Integrating Frontier
Synthetic and Proteomic
Chemistry Technologies
to Create a New Era
in Drug Discovery

Who We Are

About

Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery. Making accessible the broad set of proteins expressed in human cells, the company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA.  Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.

Redefining Druggability

  • Radical target expansion
  • Proteome-wide footprinting
  • Targets in cellular context

Vanguard
Chemistry

  • Directed spatial and chemical diversification
  • Function enhancing chemical libraries
  • Efficient & accelerated drug optimization

Therapeutic
Clarity

  • Functional phenotyping
  • Genetically validated targets
  • Pharmacodynamic endpoints
  • Accelerating proof of therapeutic impact

Platform

The company’s scientific platform allows, for the first time, protein-drug interactions to be assayed with extraordinary breadth and precision directly in native biological systems. This approach eliminates in vitro artifacts that plague traditional drug screening and defines unrecognized in situ interaction sites for drug development on known and previously undruggable targets. Vividion’s chemical proteomics platform, when coupled with cutting-edge synthetic methods and applied to compelling therapeutic targets, will provide clear, accelerated paths for development of high impact drugs. Vividion has a robust intellectual property estate that includes the assignment of numerous, heretofore unrecognized druggable sites in the human proteome.

Team

Benjamin F. Cravatt

X

Benjamin F. Cravatt is a Professor and Co-Chair of the Department of Molecular Medicine at The Scripps Research Institute. His research group is interested in understanding the roles that enzymes play in physiological and pathological processes, especially as pertains to the nervous system and cancer.  Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History.  He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. Dr. Cravatt is a co-founder and scientific advisor of Activx Biosciences, Abide Therapeutics, and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the Protein Society Irving Sigal Young Investigator Award, the Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry, the ASBMB Merck Award, and memberships in the National Academy of Sciences and American Academy of Arts and Sciences.

Phil S. Baran

X

Phil Baran received his B.S. in chemistry from NYU in 1997, his Ph.D. at The Scripps Research Institute in 2001, and from 2001-2003 he was an NIH-postdoctoral fellow at Harvard. Dr. Baran began his independent career at Scripps in the summer of 2003. He currently holds the Darlene Shiley Chair in Chemistry. He has published over 180 scientific articles and has been the recipient of several ACS awards such as the Corey (2015), Pure Chemistry (2010), Fresenius (2006), and Nobel Laureate Signature (2003), and several international distinctions such as the Hirata Gold Medal and Mukaiyama Prize (Japan), the RSC award in Synthesis (UK), and the Sackler Prize (Israel). In 2013 he was named a MacArthur Foundation Fellow, in 2015 he was elected to the American Academy of Arts and Sciences, and in 2016 he was awarded the Blavatnik National Award.

Dr. Baran has delivered hundreds of lectures around the world and consults for numerous companies such as Bristol-Myers Squibb (since late 2005), Boehringer-Ingelheim, AstraZeneca, DuPont and TEVA, and is a scientific advisory board member for Eisai, Abide, and AsymChem. In 2016 he was appointed as an Associate Editor for the Journal of the American Chemical Society. He co-founded Sirenas Marine Discovery (2012) and Vividion Therapeutics (2016) and in 2013 he co-authored The Portable Chemist’s Consultant, an interactive book published on the iBooks store along with his graduate class in Heterocyclic Chemistry (viewable for free by anyone on iTunes University). Outside of the lab, Phil enjoys spending time with his wife Ana and three young children (Lucia, Leah, and Manuel).

Jin-Quan Yu

X

Jin-Quan Yu received his B.S. in Chemistry at East China Normal University, where he worked with Professor Li-Xin Dai and Professor Bi-Qi Wu as a visiting student at Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 1987. Following a one-year course study in Shanghai Institute of Organic Chemistry, Dr. Yu went to Guangzhou Institute of Chemistry, Chinese Academy of Sciences to study terpene chemistry and heterogeneous catalysis under the supervision of Professor Shu-De Xiao and obtained his Master’s degree in 1990. He stayed on as a research associate for four years and went to Cambridge University for his doctoral studies under the supervision of Dr J. B. Spencer, where he studied biosynthesis and the mechanistic details of the hydrometallation step in asymmetric hydrogenation. Dr. Yu was elected as a Junior Research Fellow of St John’s College, Cambridge University in 1998. From 2001-2002, Jin-Quan worked on Pd-catalyzed allylic oxidation as a postdoctoral fellow at the Harvard University in the laboratories of Professor E. J. Corey. He returned to Cambridge University in 2002 and was appointed as a University Royal Society Research Fellow in 2003 to start his independent research towards developing asymmetric C–H insertion reactions. In 2004, he moved to Brandeis University as an Assistant Professor of Chemistry. He joined The Scripps Research Institute as an Associate Professor in 2007 and became a full Professor in August 2010. He was appointed as the Frank and Bertha Hupp Professor of Chemistry at The Scripps Research Institute in 2012. He received Mukaiyama Award in 2012, the Raymond and Beverly Sackler Prize in the Physical Sciences in 2013, the Elias J. Corey Award in 2014, and the MacArthur Fellowship in 2016.

John K. Clarke

X

John K. Clarke has a 30 year record of early-stage venture capital investment success. John co-founded Cardinal Partners in 1997 and currently serves as a Managing Partner of the firm. John leads Cardinal’s life sciences investment efforts and has had an extraordinary record of success.

Mr. Clarke led the firm’s investment in Cubist Pharmaceuticals, Momenta Pharmaceuticals, Alnylam Pharmaceuticals, and Sirtris Pharmaceuticals. He also spearheaded Cardinal’s investment in and served as a director for: TechRx Corporation and Visicu. Mr. Clarke currently serves on the Board of Directors for Cardinal portfolio companies Abide Therapeutics, aTyr Pharma, Rib-X Pharmaceuticals (observer) and Verastem, as well as Alnylam Pharmaceuticals and Momenta Pharmaceuticals.John entered the venture industry in 1982 with DSV Partners, a pioneer venture capital fund formed in 1968. Additionally, he led DSV’s health care and life sciences efforts, and was a co-founder and served as interim CEO of numerous successful companies including Alkermes, Arris Pharmaceuticals, DNX and Cubist Pharmaceuticals. As managing partner at DSV in that firm’s latter years, Mr. Clarke led the firm’s evolution into Cardinal Partners.

Mr. Clarke received his B.A. in Economics and Biology from Harvard University and his M.B.A. from the Wharton School at the University of Pennsylvania.

Alan Ezekowitz

X

Alan Ezekowitz currently serves as President and CEO of Abide Therapeutics, a company he co-founded in 2011 with Professors Dale Boger and Ben Cravatt from the Scripps Research Institute. Prior to creating Abide, Dr. Ezekowitz was Senior Vice President and Franchise Head, Bone, Respiratory, Immunology, Respiratory, Bone and Muscle, Dermatology and Urology at Merck Research Laboratories, where he was responsible for the drug discovery and development process from target identification through proof of concept. He worked closely with his commercial General Manager to develop the life cycle strategy for approved drugs in those areas. He co-chaired the Joint Venture with Jansen to oversee the development of Remicade and Simponi in the EU.

Prior to Merck, Dr. Ezekowitz was the Charles Wilder Professor of Pediatrics at the Harvard Medical School and served as the Chief of Pediatric Services at the MassGeneral Hospital for Children and the Partners Healthcare System. He has served on multiple boards and committees, including the chair position of the Executive Committee on Research at Massachusetts General Hospital, the Board of Directors of the Partners Healthcare system and the MassGeneral Physicians Organization. He has also served on the Boards of Anika Therapeutics and Natimmune, a biotech company that he founded. He currently serves on the Board of Directors of Oxagen and Abide Therapeutics.

Thomas O. Daniel

Executive Chairman
X

Thomas O. Daniel has contributed across a range of healthcare settings, as physician, scientist, educator, biotechnology research executive and entrepreneur, most recently serving for the past decade as President of Research & Early Development at Celgene Corporation.  Formerly in senior R&D leadership positions at Immunex, Amgen, and Ambrx, he currently advises Vanderbilt University Medical Center, and serves as director at JUNO Therapeutics, at Zafgen Inc and at several privately held companies, including Magenta Therapeutics, and Vir Therapeutics.  He is Chairman at Vividion and is a venture partner at ARCH Venture.  He advises BlackThorn Therapeutics and is on the therapeutic advisory board of aTyr Pharma.  He obtained his undergraduate degree at Southern Methodist University, his medical degree at UT-Southwestern Medical School, trained in Internal Medicine at Massachusetts General Hospital, and was formerly Hakim Professor of Medicine at Vanderbilt.

Stan Blackburn

CFO
X

Stan Blackburn joined Vividion Therapeutics in 2016 as its Chief Financial Officer. He has over 25 years of finance and accounting senior management expertise working with private venture backed life science and technology companies.

Mr. Blackburn co-founded BlackFord Partners, a consulting firm that integrates with the management of early stage companies to provide CFO financial guidance and leadership to the business’s financing strategies and financial reporting. In this role, he has closed well over $500 million in public and private equity offerings and debt financing transactions.

Mr. Blackburn has led companies through IPOs, most recently the $75 million IPO of aTyr Pharma in May 2015. Prior to founding Blackford Partners, Mr. Blackburn was a principal with Alitum, a financial advisory firm to emerging technology companies. Mr. Blackburn began his financial career at Arthur Andersen, and received his Bachelor of Arts in Accounting from the University of Illinois.

Matt Patricelli

Vice President, Biology
X

Matt Patricelli joined Vividion in 2016 as a founding scientific member of the company’s management team.  In his current role, Dr. Patricelli supports all early drug discovery efforts including target selection and validation, as well as the continued development and execution of Vividion’s chemical proteomics platform.

Prior to joining Vividion, Dr. Patricelli served as the Senior Director of Biology at Wellspring Biosciences where he led several drug discovery programs including the KRAS-G12C covalent inhibitor discovery project.  From 2000-2012 Dr. Patricelli led the chemical proteomics platform activities at ActivX Biosciences. He was the first Scientist to join ActivX and played a key role in the development of ActivX’s platform technologies, including establishing the KiNativ platform which continues to operate as a successful commercial screening service.

Dr. Patricelli obtained his BSc in Biochemistry from McGill University, and PhD from The Scripps Research Institute as the first graduate student of Vividion founder Dr. Benjamin Cravatt.  He is an author or co-author of more than 30 scientific publications, and 3 issued patents.

Dean Stamos

Vice President of Chemistry
X

Dr. Dean Stamos joined Vividion Therapeutics in 2017 as Vice President of Chemistry. In his current role, Dr. Stamos oversees the strategic growth and implementation of Vividion’s cutting edge chemical proteomics platform to support all aspects of the drug discovery process. Central towards this goal is the full utilization of modern synthetic methodologies coupled with chemical biology insights to deliver high-quality small molecule therapeutics.

Dr. Stamos joined Vividion with 20 years of leadership experience at Vertex Pharmaceuticals working in multiple therapeutic areas including infectious disease, oncology, inflammation, pain, and neurodegeneration delivering multiple pre-clinical and clinical stage assets. In addition, Dr. Stamos lead various functions integral to drug discovery including hit to lead, analytical, scale up, and library synthesis as well as the creation of an integrated chemical biology group. As a passionate supporter of exploring novelty and change at the interfaces of chemistry, biology, and leadership, Dr. Stamos initiated and chaired several internal and external collaborations in the areas of ligand-receptor kinetics, C-H activation, natural products research, and change management.

Dr. Stamos received his BS in Chemistry from Indiana University, and a PhD in Organic Chemistry from Harvard University. He is an author of 26 published articles and an inventor on 21 patents.

Todd Kinsella

Vice President of Translational and Development Sciences
X

Todd Kinsella joined Vividion in 2017 as Vice President of Translational and Development Sciences. Dr. Kinsella supports all stages of Vividion’s therapeutic pipeline from target identification, validation, drug discovery and the translational biology interface connecting pre-clinical programs and development.

Prior to joining Vividion, Dr. Kinsella served as Vice President of Research at Rigel Pharmaceuticals with over 18 years of experience in small molecule and antibody-based drug discovery. He was instrumental in establishing Rigel’s original flagship technology for discovering novel drugable targets. He has founded and served as head of numerous departments within Rigel, and led key drug discovery programs within target discovery-immunology, virology, muscle, metabolism, vascular biology and immuno-oncology.

Dr. Kinsella received his BS in Molecular and Cellular Biology from the University of Arizona and PhD in Molecular Pharmacology from Stanford University. He is an author of 15 published articles and an inventor on 26 issued patents.

Benjamin F. Cravatt

X

Benjamin F. Cravatt is a Professor and Co-Chair of the Department of Molecular Medicine at The Scripps Research Institute. His research group is interested in understanding the roles that enzymes play in physiological and pathological processes, especially as pertains to the nervous system and cancer.  Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History.  He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. Dr. Cravatt is a co-founder and scientific advisor of Activx Biosciences, Abide Therapeutics, and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the Protein Society Irving Sigal Young Investigator Award, the Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry, the ASBMB Merck Award, and memberships in the National Academy of Sciences and American Academy of Arts and Sciences.

John K. Clarke

X

John K. Clarke has a 30 year record of early-stage venture capital investment success. John co-founded Cardinal Partners in 1997 and currently serves as a Managing Partner of the firm. John leads Cardinal’s life sciences investment efforts and has had an extraordinary record of success.

Mr. Clarke led the firm’s investment in Cubist Pharmaceuticals, Momenta Pharmaceuticals, Alnylam Pharmaceuticals, and Sirtris Pharmaceuticals. He also spearheaded Cardinal’s investment in and served as a director for: TechRx Corporation and Visicu. Mr. Clarke currently serves on the Board of Directors for Cardinal portfolio companies Abide Therapeutics, aTyr Pharma, Rib-X Pharmaceuticals (observer) and Verastem, as well as Alnylam Pharmaceuticals and Momenta Pharmaceuticals.John entered the venture industry in 1982 with DSV Partners, a pioneer venture capital fund formed in 1968. Additionally, he led DSV’s health care and life sciences efforts, and was a co-founder and served as interim CEO of numerous successful companies including Alkermes, Arris Pharmaceuticals, DNX and Cubist Pharmaceuticals. As managing partner at DSV in that firm’s latter years, Mr. Clarke led the firm’s evolution into Cardinal Partners.

Mr. Clarke received his B.A. in Economics and Biology from Harvard University and his M.B.A. from the Wharton School at the University of Pennsylvania.

Thomas O. Daniel

Executive Chairman
X

Thomas O. Daniel has contributed across a range of healthcare settings, as physician, scientist, educator, biotechnology research executive and entrepreneur, most recently serving for the past decade as President of Research & Early Development at Celgene Corporation.  Formerly in senior R&D leadership positions at Immunex, Amgen, and Ambrx, he currently advises Vanderbilt University Medical Center, and serves as director at JUNO Therapeutics, at Zafgen Inc and at several privately held companies, including Magenta Therapeutics, and Vir Therapeutics.  He is Chairman at Vividion and is a venture partner at ARCH Venture.  He advises BlackThorn Therapeutics and is on the therapeutic advisory board of aTyr Pharma.  He obtained his undergraduate degree at Southern Methodist University, his medical degree at UT-Southwestern Medical School, trained in Internal Medicine at Massachusetts General Hospital, and was formerly Hakim Professor of Medicine at Vanderbilt.

Kristina Burow

X

Kristina Burow is a Managing Director with ARCH Venture Partners. Ms. Burow is a director of Vividion, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals, Metacrine, Scholar Rock, Unity Biotechnology, AgBiome and Vir Biotechnology, and was a co-founder and director of Receptos (RCPT – acquired by Celgene). She participated in other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH – acquired by Allergan), Ikaria (acquired by Madison Dearborn) and Sapphire Energy (co-founder). Prior to joining ARCH in 2002, Ms. Burow was an Associate with the Novartis BioVenture Fund and was active in Chemistry Operations and Business Development at the Genomics Institute of the Novartis Research Foundation. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.

Thomas Woiwode

X

Thomas Woiwode has been with Versant Ventures since 2002, serving as a Venture Partner since 2011 and a Managing Director since 2014.  Mr. Woiwode has served in a number of operating roles over this time, most recently as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases. He led the process that culminated in the sale of Okairos to GlaxoSmithKline for $325M. Prior to his role with Okairos, Mr. Woiwode co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb for up to $475M). Prior to his role as a Venture Partner, he was an Associate at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. Mr Woiwode was a research scientist at XenoPort before joining Versant. He earned his PhD in Organic Chemistry as an NSF Fellow at Stanford University and graduated summa cum laude with a BA in English and received the Departmental Citation for his B.S. in Chemistry from UC Berkeley.

Mr. Woiwode currently serves on the boards of Annapurna, Anokion, Audentes, CRISPR, Gritstone, Kanyos Bio, and Therachon.

Paul Schimmel

X

Paul Schimmel earned his Ph.D. in biology at MIT in 1966 and was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT. Dr. Schimmel is author or co-author of more than 450 scientific papers and of a widely used three volume textbook on biophysical chemistry. Schimmel has been honored as an elected member of the American Academy of Arts and Sciences, the National Academy of Sciences, the American Philosophical Society, and the Institute of Medicine. Having a longstanding interest in the applications of basic biomedical research to human health, Schimmel holds numerous patents and is a cofounder or founding director of several biotechnology companies, of which seven became NASDAQ-listed, publicly traded stocks.

Investors

Contact

Vividion Therapeutics
information@vividion.com

Media Contact
Katie Engleman
kengleman@purecommunications.com
910.509.3977